A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Karyopharm

Protocol Number
KCP-330-009

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Constellation

Protocol Number
Constellation 1205-01

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
Incyte

Protocol Number
INCB 50465-203

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

Clinical outcomes following ibrutinib and idelalisib-based therapy in CLL: A retrospective analysis

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00005855

To Learn More Call
201-510-0910

Phase 1/2 Proof of Concept study investigating acalabrutinib in combination with vistusertib in subjects with Relapsed/Refractory B-cell malignancies

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-110

To Learn More Call
201-510-0910

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with R